The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section.

Suppr

超能文献

出版信息

Stroke. 1973 Jul-Aug;4(4):684-93. doi: 10.1161/01.str.4.4.684.

DOI:10.1161/01.str.4.4.684

PMID:4723698

Abstract

摘要

相似文献

The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section.

Stroke. 1973 Jul-Aug;4(4):684-93. doi: 10.1161/01.str.4.4.684.

Estrogenic therapy in men with ischemic cerebrovascular disease: effect on recurrent cerebral infarction and survival. Final report of the Veterans Administration cooperative study of atherosclerosis, neurology section.缺血性脑血管疾病男性患者的雌激素治疗：对复发性脑梗死和生存的影响。退伍军人管理局动脉粥样硬化合作研究神经科部分的最终报告。

Stroke. 1972 Jul-Aug;3(4):427-33. doi: 10.1161/01.str.3.4.427.

[Statistics for the study of cerebrovascular insufficiency due to occlusive or stenotic lesions of the carotid artery. I].

Rass Int Clin Ter. 1971 May 15;51(9):534-42.

Clofibrate in coronary heart disease. Effect on morbidity and mortality.

JAMA. 1972 Feb 14;219(7):845-51.

Clofibrate and niacin in coronary heart disease.氯贝丁酯与烟酸治疗冠心病

JAMA. 1975 Jan 27;231(4):360-81.

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.缺血性心脏病：一项使用氯贝丁酯的二级预防试验。苏格兰医师协会研究委员会的报告。

Br Med J. 1971 Dec 25;4(5790):775-84.

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.氯贝丁酯治疗缺血性心脏病的试验。泰恩河畔纽卡斯尔地区一组医生进行的五年研究。

Br Med J. 1971 Dec 25;4(5790):767-75.

Impotence in patients treated with clofibrate.接受氯贝丁酯治疗的患者出现阳痿。

Atherosclerosis. 1975 May-Jun;21(3):455-7. doi: 10.1016/0021-9150(75)90057-x.

Clofibrate for prevention of myocardial infarction.

Med Lett Drugs Ther. 1973 Apr 27;15(9):37-8.

Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.使用氯贝丁酯的二级预防试验：关于纽卡斯尔和苏格兰试验的联合评论

Br Med J. 1971 Dec 25;4(5790):784-6. doi: 10.1136/bmj.4.5790.784.

引用本文的文献

Targeting Cardiac Metabolism in Heart Failure with PPARα Agonists: A Review of Preclinical and Clinical Evidence.使用PPARα激动剂靶向心力衰竭中的心脏代谢：临床前和临床证据综述

Biomedicines. 2025 Aug 26;13(9):2080. doi: 10.3390/biomedicines13092080.

Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.靶向高密度脂蛋白治疗对心血管结局的影响：系统评价和荟萃分析。

Eur J Prev Cardiol. 2019 Mar;26(5):533-543. doi: 10.1177/2047487318816495. Epub 2018 Dec 6.

Fibrates for primary prevention of cardiovascular disease events.贝特类药物用于心血管疾病事件的一级预防。

Cochrane Database Syst Rev. 2016 Nov 16;11(11):CD009753. doi: 10.1002/14651858.CD009753.pub2.

All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.所有降胆固醇干预措施预计均可降低中风风险：来自IMPROVE-IT的确证数据。

Data Brief. 2016 Apr 27;7:1541-50. doi: 10.1016/j.dib.2016.04.059. eCollection 2016 Jun.

Fibrates for secondary prevention of cardiovascular disease and stroke.贝特类药物用于心血管疾病和中风的二级预防。

Cochrane Database Syst Rev. 2015 Oct 25;2015(10):CD009580. doi: 10.1002/14651858.CD009580.pub2.

Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.在一项血脂修饰试验中，以基线糖尿病作为预测心血管结局的方法：对来自47项具有里程碑意义的研究的330376例患者进行的荟萃分析。

Cardiovasc Diabetol. 2015 May 21;14:60. doi: 10.1186/s12933-015-0226-z.

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.高密度脂蛋白靶向药物治疗烟酸、贝特类药物和胆固醇酯转运蛋白抑制剂对心血管风险的影响：纳入117411例患者的随机对照试验的荟萃分析

BMJ. 2014 Jul 18;349:g4379. doi: 10.1136/bmj.g4379.

Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention.预防中风的血脂管理：贝特类药物预防中风的荟萃分析。

BMC Neurol. 2013 Jan 3;13:1. doi: 10.1186/1471-2377-13-1.

Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.使用贝特类药物和癌症风险：17 项长期随机安慰剂对照试验的系统评价和荟萃分析。

PLoS One. 2012;7(9):e45259. doi: 10.1371/journal.pone.0045259. Epub 2012 Sep 19.

Fibrates consistently lower risk of cardiovascular events across high-risk groups.贝特类药物持续降低高危人群发生心血管事件的风险。

Cardiovasc J Afr. 2010 May-Jun;21(3):174.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验